Trade.Information

Topic Name: Factors of Prostate Cancer Risk

Category: Biomedical

Research persons: David Reich, & Christopher Haiman
Also involved researchers at Massachusetts General Hospital, Dana-Farber Cancer Institute and the University of Michigan.

Location: Health Sciences Campus, University of Southern California, Los Angeles, CA 90033. (323) 442-2000, United States

Details

A study led by researchers at the Keck School of Medicine of USC and Harvard Medical School has identified seven genetic risk factors – DNA sequences carried by some people but not others – that predict risk for prostate cancer. According to the study’s findings, these risk factors are clustered in a single region of the human genome on chromosome 8 and powerfully predict a man’s probability of developing prostate cancer. The paper is published in the online edition of Nature Genetics on April 1. “The study has identified combinations of genetic variants that predict more than a fivefold range of risk for prostate cancer,” said senior author David Reich, assistant professor of genetics at Harvard Medical School and associate member of the Broad Institute of Harvard and MIT. “Both high- and low-risk combinations of variants are common in human populations.” Added lead author Christopher Haiman, assistant professor of preventive medicine at the Keck School of Medicine, “The identification of these genetic variants is an important step in helping us understand the higher risk for prostate cancer in African-Americans compared with other U.S. populations and, more importantly, why some men develop prostate cancer and others do not.” While the Harvard-USC team identified seven genetic variants on chromosome 8, two other studies published in the same issue of Nature Genetics highlight the importance of this region in prostate cancer, and each provides independent support for the findings presented by the Harvard-USC team. One of the studies is from deCODE Genetics in Iceland while the other is led by Gilles Thomas and Stephen Chanock at the National Cancer Institute. Together, the three studies provide robust evidence of the role genetic variants play in prostate cancer. According to the Harvard-USC study, the seven genetic variants each independently predict risk for prostate cancer, with the predictive strength varying depending on the variant. Because almost all the risk factors were of highest frequency in African-Americans, they may contribute to the known higher rate of prostate cancer among African-Americans compared with other U.S. populations. The predictive power of the variants may also be useful in the prevention of prostate cancer. “Clinical testing of these genetic variants may help us identify men who should be prioritized for early prostate cancer screening and prevention efforts,” Reich said. The study also produced novel biological findings. It revealed that each genetic contributor to prostate cancer risk is located outside of the coding regions of genes, in regions previously designated as junk DNA. “The discovery of multiple, independent genetic changes that are in close proximity to one another, but outside of any known gene, suggests that these results may also teach us about novel molecular mechanisms whereby DNA changes can alter risk of disease,” said Brian Henderson, the paper’s senior co-author and dean of the Keck School of Medicine. Two papers in 2006 highlighted this same chromosomal region as important in prostate cancer. deCODE genetics in Iceland first identified two specific genetic variants that contributed to risk for prostate cancer. The Harvard-USC group then published a paper that identified a small region (about 4 million nucleotides, or 1/1,000th of the genome) as likely to contain important genetic risk factors. As part of this study, the Harvard-USC group carried out a whole-genome screen for prostate cancer genes in about 2,500 African-Americans. The paper suggested that more variants were likely in the region. To find the additional risk factors in the current study, the team systematically tested genetic changes in this region of the genome in roughly 7,500 African-American, Japanese-American, Native Hawaiian, Latino and European-American men with and without prostate cancer. The majority of the men studied were drawn from the Multiethnic Cohort Study, an epidemiological study of more than 215,000 people from Los Angeles and Hawaii created in 1993 by USC’s Henderson and Laurence Kolonel of the University of Hawaii. The genetic study of the MEC grew out of a multiyear, ongoing collaboration between USC, the University of Hawaii and collaborators at Harvard Medical School and the Broad Institute of Harvard and MIT. The study also involved researchers at Massachusetts General Hospital, Dana-Farber Cancer Institute and the University of Michigan. About researchers: David Reich, Assistant Professor Harvard Medical School, Department of Genetics Associate Member, Broad Institute of Harvard and MIT New Research Building, Room 336 77 Avenue Louis Pasteur Boston, MA  02115 USA Directions to Laboratory Tel: (1) 617-432-6548 Fax: (1) 617-432-6306 E-mail: reich@genetics.med.harvard.edu Christopher Haiman Assistant Professor,Preventive medicine at the Keck School of Medicine. NOR 4441, 9175 Phone: (323) 865-0429 Fax: (323) 865-0127 E-mail: haiman@usc.edu Funded: The National Institutes of Health and the National Cancer Institute provided funding for this study.